Advertisement

Search Results

Advertisement



Your search for ,maY matches 16737 pages

Showing 4401 - 4450


solid tumors
covid-19

Many Patients With Solid Tumors Mount an Adequate Response to SARS–CoV-2 Vaccine, Dutch Study Reports

Individuals with solid tumors had an appropriate, protective immune response to vaccination against SARS–CoV-2, at least with the mRNA-1273 vaccine, and side effects were no more common than in the general population, according to a large Dutch study.1 The study was reported during the European...

issues in oncology
cost of care

Expert Point of View: Michaela A. Dinan, PhD

Invited discussant of the study on medication nonadherence, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, in Connecticut, noted that the CAHPS survey data provide...

issues in oncology
cost of care

Medication Nonadherence Among Cancer Survivors: Are Indirect Health-Care Costs to Blame?

Approximately 1 in 10 long-term survivors of cancer fails to take medications as prescribed due to financial hardship, according to research presented at the 2021 ASCO Quality Care Symposium.1 However, indirect health-care costs—not drug copays—may be responsible, the study investigators ...

Susan G. Komen Announces $1.5 Million in Grants for Metastatic Breast Cancer Research

Susan G. Komen, the world’s leading breast cancer organization, recently announced the award of $1.5 million for three new research projects that examine unique areas focused on metastatic breast cancer. The grants are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research...

issues in oncology

Arginine May Enhance Effectiveness of Radiation Therapy for Brain Metastases

Treatment with arginine, an amino acid, enhanced the effectiveness of radiation therapy in patients with cancer and brain metastases in a proof-of-concept, randomized clinical trial published by Marullo et al in Science Advances. The recently published paper reported the results of administering...

breast cancer

Fear of Side Effects and Lack of Awareness: Barriers to Greater Use of Risk-Reducing Medications for Breast Cancer

A “big problem, maybe the major one,” with risk-reducing medications for breast cancer is low uptake among women at high risk of breast cancer,” Seema A. Khan, MD, told participants at the 2021 Annual Lynn Sage Breast Cancer Symposium.1 Dr. Khan is Professor of Surgery and the Bluhm Family...

breast cancer

Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable

Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...

prostate cancer

Racial Disparities in Use of Prostate MRI After Detection of Elevated PSA Levels

In a study published by Abashidze et al in JAMA Network Open, the investigators found that Black men were at least 23.6% less likely than White men to undergo magnetic resonance imaging (MRI) following an elevated prostate-specific antigen (PSA) test result. They also found that Hispanic and Asian...

lung cancer
genomics/genetics

Adjuvant Gefitinib vs Cisplatin/Vinorelbine for Completely Resected EGFR-Mutant Stage II to IIIA NSCLC

In the Japanese phase III IMPACT trial reported in the Journal of Clinical Oncology, Tada et al found that adjuvant gefitinib did not improve disease-free survival vs cisplatin/vinorelbine in patients with completely resected stage II to IIIA EGFR-mutant non–small cell lung cancer (NSCLC). In the...

issues in oncology

Study Finds Lack of Health Insurance May Hinder Recommended Cancer Screening in Unemployed Adults

In a recent study published by Stacey Fedewa, PhD, and colleagues in the journal Cancer, unemployed individuals were less likely to have health insurance and be up to date on getting recommended cancer screening tests. Analyses revealed that their lack of health insurance coverage accounted for...

lung cancer

NSCLC in the United States: Update on Incidence, Prevalence, and Survival

In a study reported in JAMA Oncology, Apar Kishor Ganti, MD, MS, and colleagues found that the incidence of non–small cell lung cancer (NSCLC) has decreased in the United States in recent years. They also found that prevalence has increased, likely in association with more effective treatment and...

issues in oncology

Early Warning System Model May Help to Predict Deterioration of Hospitalized Patients With Cancer

About 9% of patients with cancer experience complications while hospitalized that lead to a deterioration in their condition, a transfer to the intensive care unit, or death. A multidisciplinary team of researchers at Washington University in St. Louis is developing a machine learning–based early...

lymphoma

Ibrutinib Plus R-CHOP for Younger Patients With DLBCL

New evidence suggests that adding the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib to a standard chemotherapy regimen may improve survival among younger people with a specific form of diffuse large B-cell lymphoma (DLBCL). The findings, published by Wyndham Wilson, MD, PhD, in Cancer Cell,...

breast cancer

Adjuvant Internal Mammary Node Irradiation in Node-Positive Breast Cancer

In a Korean phase III trial reported in JAMA Oncology, Kim et al found that the addition of internal mammary node irradiation to adjuvant regional nodal irradiation did not improve 7-year disease-free survival in women with node-positive breast cancer. In an ad hoc analysis, however, benefit was...

prostate cancer

Studies Find B7-H3 Protein May Be a Target for Prostate Cancer Treatment

The immune checkpoint protein B7-H3 may be a potential new target in treatment-resistant prostate cancers, according to two studies presented recently at the European Society for Medical Oncology (ESMO) Congress 2021. “Virtually every prostate cancer cell expresses some degree of B7-H3, which...

breast cancer
genomics/genetics

Germline Pathogenic Variants in Cancer Predisposition Genes and Risk for Invasive Lobular Carcinoma of the Breast

In a study reported in the Journal of Clinical Oncology, Yadav et al found that germline pathogenic variants in the cancer predisposition genes ATM, BRCA2, CDH1, CHEK2, and PALB2 were associated with an increased risk of invasive lobular carcinoma of the breast, with no association with BRCA1...

lymphoma
survivorship

Study Finds Younger B-Cell Non-Hodgkin Lymphoma Survivors May Have a Higher Risk of Age-Related Diseases Than Older Survivors

Non-Hodgkin lymphoma is one of the most common cancers diagnosed in the United States, accounting for nearly 4% of all cancers. This year, about 81,600 individuals will be diagnosed with non-Hodgkin lymphoma, and nearly 21,000 will die from the cancer. A study by Ocier et al published in Cancer...

prostate cancer

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may...

cost of care

Expert Point of View: Michaela A. Dinan, PhD

The invited discussant of the study on out-of-pocket costs of cancer care, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, Connecticut, underscored the study’s key...

cost of care

Out-of-Pocket Costs on the Rise for the Four Most Common Cancers, Study Finds

Rising cost-sharing requirements from private insurance have exacerbated the financial burden for patients with cancer, according to research presented at the 2021 ASCO Quality Care Symposium.1 Analysis of claims data on the four most prevalent cancers in the United States—female breast,...

leukemia

Study Finds Type I Interferon May Enhance the Antileukemia Effect of Allogeneic Transplantation

In a study published by Magenau et al in the journal Blood Advances, researchers found that patients with high-risk acute myeloid leukemia (AML) who received a form of type I interferon after allogeneic hematopoietic stem cell transplant experienced reduced rates of disease relapse. Additionally,...

gastrointestinal cancer

Addition of FDG-PET/CT and Staging Laparoscopy to the Initial Staging of Locally Advanced Gastric Cancer

In a Dutch cohort study (PLASTIC) reported in JAMA Surgery, Gertsen et al found that staging laparoscopy provided more diagnostic information resulting in change of treatment intent than F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) in patients with...

issues in oncology

Do Solid Organ Transplant Recipients With a Previous Cancer Diagnosis Have High Cure Probabilities?

In a study reported in the Journal of Clinical Oncology, Engels et al found that patients with a previous cancer diagnosis who underwent solid organ transplantation had high cancer cure probabilities. Additionally, posttransplantation cancer-specific survival was associated with cancer cure...

breast cancer
lung cancer
issues in oncology

Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers

Matthew Manning, MD, of Cone Health Cancer Center, discusses findings that showed changes to the way cancer care is delivered may help eliminate racial disparities in survival among patients with early-stage lung and breast cancers. Identifying and addressing obstacles that kept patients from...

prostate cancer

Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression

Benjamin Movsas, MD, of the Henry Ford Cancer Center, discusses results from the NRG Oncology/RTOG 0815 study, which explored dose-escalated radiotherapy alone or in combination with short-term hormonal therapy for patients with intermediate-risk prostate cancer. In addition to clinical outcomes,...

gastrointestinal cancer

Areej El-Jawahri, MD, on the Significance of Patient-Reported Outcomes in Gastrointestinal Cancers

The invited discussant of this study on patient-reported outcomes, Areej El-Jawahri, MD, Associate Director of Cancer Outcomes Research and Education Program and Director of Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital, said these findings underscore the importance...

gastrointestinal cancer

Patient-Reported Outcomes in Gastrointestinal Cancers: Predicting Treatment Response and Survival Outcomes

According to data presented during the 2021 ASCO Quality Care Symposium,1 1-month changes in patient-reported outcomes may predict treatment response and survival outcomes in patients with advanced gastrointestinal cancers. The results of a prospective study of 159 patients with metastatic...

survivorship

Effect of Social Determinants of Health on Receipt of Survivorship Care Plans

Survivorship care plans are an important tool to help cancer survivors transition from active treatment to follow-up care, but a study published by Timsina et al in Supportive Care in Cancer has found that a number of vulnerable groups have a lower likelihood of receiving such plans. Cancer...

lung cancer
covid-19

Study Evaluates Virtual vs In-Person Visits and Access to Lung Cancer Screening

Findings from a novel telemedicine effort to screen patients for lung cancer screening during the COVID-19 pandemic show that virtual single-visit screenings may be just as effective as single-visit screenings done in person, according to a study presented by Magarinos et al at the American College ...

breast cancer
lung cancer

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the first randomized trial of stereotactic body radiation therapy (SBRT) to treat oligoprogressive, metastatic lung and breast cancers. The standard of care for patients with these types of tumors is to...

prostate cancer

Do Diet-Related Molecules Play a Role in the Development of Aggressive Prostate Cancer?

Cleveland Clinic researchers have shown that diet-associated molecules in the gut may be associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. These findings were published by Reichard et al in Cancer Epidemiology, Biomarkers & Prevention.  While...

pancreatic cancer

Study Finds Incidence of Pancreatic Cancer May Be Rising in Younger Women

The incidence of pancreatic cancer—which historically has been higher in men than in women—has increased among both men and women during the past decade, with a significantly greater relative increase observed in women younger than age 55 years, and especially among those aged 15 to 34 years. These ...

breast cancer
gastrointestinal cancer
genomics/genetics

Rates of Occult Gastric Carcinoma in Patients With Hereditary Lobular Breast Cancer Due to CDH1 Genetic Variants

In a single-institution prospective cohort study reported in JAMA Surgery, Gamble et al found that patients with hereditary lobular breast cancer due to CDH1 variants also had a high prevalence of occult signet ring cell gastric carcinoma. Study Details The study involved 283 patients from 151...

multiple myeloma
covid-19

Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination

Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...

prostate cancer

Hypofractionated Postoperative Prostate Bed Radiotherapy Does Not Increase Patient-Reported Toxicity for Men With Prostate Cancer

A primary endpoint analysis of the NRG Oncology phase III NRG-GU003 clinical trial, which compared hypofractionated postoperative prostate bed radiotherapy (HYPORT) to conventional postprostatectomy radiotherapy (COPORT) for men with prostate cancer, determined that treatment with HYPORT yielded no ...

leukemia
genomics/genetics

Addition of Enasidenib to Azacitidine in Newly Diagnosed IDH2-Mutant Acute Myeloid Leukemia

As reported in The Lancet Oncology by Courtney D. DiNardo, MD, and colleagues, an interim analysis of the phase II portion of a phase Ib/II trial (AG221-AML-005) showed that the addition of the oral mutant IDH2 protein inhibitor enasidenib to azacitidine significantly improved overall response rate ...

lung cancer
immunotherapy

Nivolumab for Relapsed Malignant Mesothelioma: Improvements in Progression-Free and Overall Survival

In the phase III CONFIRM trial reported in The Lancet Oncology, Dean A. Fennell, FRCP, PhD, and colleagues found that nivolumab improved progression-free and overall survival vs placebo in patients with relapsed malignant mesothelioma. In October 2020, the combination of nivolumab and ipilimumab...

prostate cancer

Phase III Trial Evaluates Efficacy of Total Androgen Suppression Plus Dose-Escalated Radiotherapy for Patients With Intermediate-Risk Prostate Cancer

Both dose-escalated radiation therapy and short-course androgen-deprivation therapy (SADT) have been shown to improve outcomes in patients with intermediate-risk prostate cancer. Researchers then posed a new question—is giving both modalities upfront to newly diagnosed patients of benefit? Findings ...

hepatobiliary cancer

Study Examines Use of External-Beam Radiotherapy as a Bridging Therapy for Patients With HCC Awaiting Transplant

Patients with hepatocellular carcinoma (HCC) awaiting liver transplantation may benefit from noninvasive treatment with external-beam radiotherapy (EBRT) but are rarely given this therapy, according to a new analysis of U.S. national data. Findings were presented by Nima Nabavizadeh, MD, at the...

cost of care

Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care

Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...

cns cancers
genomics/genetics

Diana D. Shi, MD, on IDH-Mutant Gliomas: De Novo Pyrmidine Synthesis Inhibitor Under Study

Diana D. Shi, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Cancer Center, discusses studies being planned and already underway to test BAY 2402234, a de novo pyrimidine synthesis inhibitor that possibly could be used clinically to target IDH-mutant gliomas and may act as a...

colorectal cancer

KRAS G12C Inhibitor Adagrasib Shows Activity in Colorectal Cancer

Adagrasib, a covalent inhibitor of KRAS G12C, combined with cetuximab, showed activity in patients with metastatic colorectal cancer in the phase I/II KRYSTAL-1 trial, as presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021 by Jared Weiss, MD,...

issues in oncology

Study Finds Prior Authorization Costs Academic Radiation Oncology Clinics More Than $40 Million Every Year

The time required to secure prior authorization approvals for radiation therapy equates to a financial impact of more than $40 million annually for academic medical centers, according to a new study presented by Bingham et al at the 2021 American Society for Radiation Oncology (ASTRO) Annual...

Expert Point of View: Arjun Gupta, MBBS

Moderator of the session on oncology drug pricing, Arjun Gupta, MBBS, Assistant Professor of Medicine at the University of Minnesota Medical School, observed that generics alone may be insufficient to slow the astronomical rise of drug prices. “The general thinking has always been that generics...

breast cancer
lung cancer
issues in oncology

ACCURE Trial Aims to Eliminate Disparities in Survival in Black and White Patients With Early-Stage Lung and Breast Cancers

A study presented by Manning et al at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 53) showed that interventions to help Black patients overcome obstacles to completion of treatment can impact disparities in survival outcomes between Black and White patients...

prostate cancer

22-Gene Classifier Score May Allow for Personalization of Therapy in Patients With High-Risk Prostate Cancer

A 22-gene genomic classifier (the Decipher score) may be able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented by Paul L. Nguyen, MD, at the 2021 American Society for Radiation Oncology...

lung cancer

Having Stage IV Lung Cancer Has Refocused My Life

The first indication I had stage IV lung cancer was a persistent cough during the beginning of the cold-and-flu season in the fall of 2013. I was 35 years old, never smoked, and in otherwise excellent health, so I ignored the cough for several months until I noticed my breathing had also become...

integrative oncology

Acupuncture vs Cognitive Behavioral Therapy for Cognitive Function in Cancer Survivors With Insomnia

Guest Editor’s Note: Cancer-related cognitive difficulties, experienced by many cancer survivors, include perceived or objective deficits in memory, attention, and concentration, which can negatively impact quality of life. Given the important role that healthful sleep plays in cognitive processes, ...

breast cancer
global cancer care

Urbanization in Bangladesh: The Prevalence of Breast Cancer Brings Unique Challenges

The number of deaths related to breast cancer are increasing at an alarming pace worldwide. According to a World Health Organization (WHO) 2020 report, approximately 2,088,849 new cases and 627,000 deaths related to breast cancer occurred in 2018.1 More than 55% of these deaths occurred in low- to ...

issues in oncology

Extended Open Enrollment, Special Enrollment Periods Finalized for Some Insurance Exchanges, Increasing Access to Cancer Care

On September 17, 2021, the Centers for Medicare & Medicaid Services (CMS) finalized a rule that could increase access to cancer care through an extended open enrollment period and monthly special enrollment periods for federally facilitated health insurance exchanges and state-based exchanges...

Advertisement

Advertisement




Advertisement